Celgene drug fares well in Behcet's syndrome trial

10/31/2013 | PharmaTimes (U.K.)

A midstage study found that Celgene's experimental drug apremilast was effective in improving symptoms for patients with Behcet's syndrome. According to the study, more patients who took apremilast were free from oral and genital ulcers after 12 weeks of treatment than those who took a placebo.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Fridley, MN
Product Patent Attorney
Foster City, CA
Employment Counsel
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC